Peroxisome proliferator-activated receptors (PPARs) were reported to prevent cells from stress-induced apoptosis and protect tissues against ischemia-reperfusion injury. The underlying transcriptional mechanism is unclear. Recent reports indicate that the antiapoptotic actions of ligand-activated PPARδ and PPARγ are mediated through enhanced binding of PPAR to the promoter of 14-3-3ε and upregulation of 14-3-3ε expression. We propose that ligand-activated PPARα exerts its anti-apoptotic actions via the identical pathway. The PPAR to 14-3-3 transcriptional axis plays an important role in protection of cell and tissue integrity and is a target for drug discovery.
Introduction
Peroxisome proliferator-activated receptors (PPAR) are nuclear receptors that mediate diverse metabolic and cellular functions. They comprise three members: PPAR-α, PPAR-γ, and PPAR-δ (also known as PPAR-β), which have a high degree of sequence homology and share common structural characteristics (For review see [1] ). In addition to their well-recognized actions on regulating lipid metabolism and glucose homeostasis, PPARs are involved in diverse functions such as cell survival, proliferation, differentiation and inflammation [2, 3] . There is an increasing evidence that all three PPAR isoforms are crucial for defending against apoptosis induced by oxidative and metabolic stresses. However, the mechanism by which ligand-activated PPARs defend against apoptosis is largely unknown. Recently, it was reported that ligand-activated PPARδ and PPARγ exert antiapoptotic actions by transcriptional upregulation of 14-3-3ε [4] . Here, we review the reported data and propose a common anti-apoptotic mechanism.
Prostacyclin Protects Cells from Stress-Induced Apoptosis
Prostacyclin (PGI 2 ) is a metabolite of arachidonic acid (AA). Its biosynthesis is requires the coordinated actions of (1) phospholipase A 2 which liberates AA from membrane phospholipids, (2) cyclooxygenase (COX, also known as prostaglandin H synthase) which converts AA into PGH 2 , and (3) prostacyclin synthase (PGIS) which converts PGH 2 into PGI 2 [5] . The PGI 2 synthetic enzymes are expressed in several cell types including vascular endothelial and smooth muscle cells, cardiac cells, renal interstitial cells, and certain cancer cells. PGI 2 possesses multiple biological actions and plays important roles in important physiological and pathological functions. Extensive investigations have established its platelet inhibitory and vasodilatory actions and its essential function in vascular homeostasis [6] [7] [8] . The classic actions of PGI 2 on inhibition of platelet aggregation and vasoconstriction are mediated via I-type prostaglandin (IP) membrane receptor which signals through protein kinase A pathway [9] . Recent studies have reported that PGI 2 protects diverse cells against stress-induced apoptosis; it protects renal interstitial cells from hypertonicity-induced apoptosis, cardiomyocytes from doxorubicin-induced apoptosis and megakaryocytes from nitric oxide-(NO-) induced apoptosis. [10] [11] [12] . The published reports imply that its anti-apoptotic action is mediated via PPAR. First, synthetic PGI 2 analogs including carbaprostacyclin (cPGI 2 ) and iloprost were reported to bind PPARδ and PPARα [13] . Second, protection of renal interstitial cells against hypertonicity-induced apoptosis by PGI 2 was correlated with PPARδ activation [14] . Third, PPARδ was reported to protect against apoptosis in keratinocytes [15] , cardiomyocyte [16] , islet β cell [17] , and smooth muscle cells [18] . [4] . Intraventricular infusion of Ad-COPI into ischemic brain significantly reduces infarct volume induced by ischemia-reperfusion (I/R) in a rat stroke model [19] . Intraventricular infusion of Ad-COPI in rats is accompanied by a 4-fold increase in PGI 2 and a significant reduction of other prostaglandins and leukotrienes in the ipsilateral brain tissues, consistent with a metabolic shift to PGI 2 synthesis in vivo [19] . Administration of Ad-COPI to rats several hours after I/R injury remains effective in reducing cerebral infarction volume [19] . These results suggest that authentic PGI 2 production via Ad-COPI transfection suppresses apoptosis and reduces the extent of brain infarction. The anti-apoptotic effect of Ad-COPI in HUVECs is abrogated by cotransfection with a selective PPARδ small interference RNA (siRNA) but not a control RNA. It is estimated that the authentic PGI 2 generated by gene transfer is effective in protecting against apoptosis and I/R-induced damage at nM concentrations. In contrast, PGI 2 
Ligand-Activated PPARδ Binds and
Upregulates 14-3-3ε Promoter 14-3-3 is identified as a target of ligand-activated PPARδ through candidate gene screening. 14-3-3 proteins function as a scaffold to regulate the activities of kinases, facilitate intracellular translocation of diverse proteins, and control apoptosis [20] . Human 14-3-3 comprises seven members, all of which are constitutively expressed in HUVECs. cPGI 2 and L-165041 increase the expression primarily of 14-3-3ε proteins [4] . PPARδ ligands stimulate the 14-3-3ε promoter activity to an extent comparable to 14-3-3 protein.
14-3-3ε promoter does not have TATA-box but harbors three PPAR response elements (PPRE) [4] . Deletion of the PPRE elements from the promoter construct abolishes the promoter stimulating effect of cPGI 2 or L-165041. Analysis of PPARδ binding to the PPRE region by chromatin immunoprecipitation reveals that PPARδ ligands enhance binding of PPARδ to the PPRE-containing fragment but not to a distal segment that does not contain PPRE motifs. Thus, ligand-activated PPARδ binds directly to its binding sites on 14-3-3ε promoter and upregulates 14-3-3ε expression.
PPARδ-Mediated 14-3-3ε Upregulation Enhances Bad Sequestration
The constitutively expressed 14-3-3ε proteins serve as a gatekeeper to defend against apoptosis via the mitochondrial death pathway by sequestering Bad, Bax, and Foxo [21] . However, the basal 14-3-3 levels are inadequate for controlling apoptosis when the cells are challenged with excessive stresses. The ligand-activated PPARδ plays an important role in conferring the anti-apoptotic defense by upregulating 14-3-3ε expression. [22] . Taken together, these results indicate that 14-3-3ε upregulation by PPARδ ligands has an important functional impact on controlling oxidant-induced apoptosis.
Nonsteroidal Anti-Inflammatory Drugs Induce Apoptosis by Suppressing PPARδ/14-3-3ε
A number of nonsteroidal anti-inflammatory drugs (NSAIDs) induce normal and cancer cell apoptosis in a cyclooxygenase-2-(COX-2-) dependent or independent manner [23] [24] [25] . The exact mechanisms by which NSAIDs induce apoptosis are not entirely clear. One potential mechanism involves the PPARδ transcriptional pathway. It was reported that PPARδ in colorectal cancer cells promotes cell proliferation [26, 27] and NSAIDs induce colon cancer cell apoptosis by suppressing PPARδ [28] . Results from our laboratories have shown that sulindac sulfide and indomethacin suppress PPARδ expression with corresponding inhibition of 14-3-3ε promoter activity and protein expression [29] . Downregulation of 14-3-3ε is accompanied by reduced Bad sequestration by 14-3-3ε and increased translocation of Bad to mitochondria leading to apoptosis via the mitochondrial death pathway. NSAIDinduced apoptosis is attenuated by 14-3-3ε overexpression. The proapoptotic effect of NSAIDs is not restricted to cancer PPAR Research 3 cells. Sulindac and indomethacin induce HUVEC apoptosis by suppressing PPARδ/14-3-3ε and thereby enhancing Badmediated cell death via mitochondrial damage [30] . Thus, suppression of PPARδ/14-3-3ε transcriptional pathway represents a major mechanism by which NSAIDs induce cell death.
Conflicting Effects of PPARγ Agonists on Cell Survival
PPARγ agonists such as thiazolidinediones (for example, rosiglitazone, and pioglitazone) and prostaglandin D 2 metabolites (15-deoxy-Δ 12,14 -PGJ 2 ) regulate cell survival but the results are conflicting. PPARγ agonists were reported to induce apoptosis in different types of cells including endothelial cells, vascular smooth muscle cells, and cancer cells [31, 32] . On the other hand, rosiglitazone was reported to protect cardiomyocytes, β islet cells, and neurons against apoptosis [33] [34] [35] . The reasons for the conflicting results in those reports are unclear but may be explained by use of different concentrations of PPARγ agonists, different cell types, and/or PPARγ-independent actions of the agonists [36] . It was reported that thiazolidinediones at concentrations that activate the PPARγ transcriptional activity protect cell survival while at higher concentrations they induce apoptosis [37] . We have evaluated concentrationdependent effects of rosiglitazone on neuronal apoptosis and I/R brain damage. Rosiglitazone exerts a biphasic effect on hypoxia/reoxygenation-induced neuronal apoptosis and I/R-induced brain damage. At low in vitro concentrations (<5 μM) and low in vivo doses (<50 ng) in a rat stroke model, rosiglitazone protects against neuronal apoptosis and attenuates cerebral infarct volume while at high concentrations and doses, rosiglitazone does not have any protective effect and may aggravate the hypoxia and ischemia-induced cell and tissue damage [35] . The mechanism by which thiazolidinedione and 15d-PGJ 2 exert a biphasic concentrationdependent effect on cell and tissue protection is unclear and requires further investigations.
Rosiglitazone Protects against Ischemia/Reperfusion-Induced Cerebral Infarction via PPARγ-Mediated 14-3-3ε Upregulation
In order to understand how PPAR-γ agonists reduce brain tissue damage by I/R, we have evaluated the effect of 15d-PGJ 2 (10 pg) or rosiglitazone (50 ng) on I/R-induced infarction volume by intraventricular infusion. At the relatively low doses used, the PPAR-γ agonists reduced the infarct volume to a similar extent [35, 38] . Further investigations reveal that rosiglitazone is effective in reducing the infarct volume when it is infused 2 hours after I/R [35] . The protective effect of rosiglitazone is abrogated by GW9662, a PPARγ antagonist as well as by PPARγ siRNA. On the other hand, cerebral infarction is rescued by overexpression of PPARγ. Results from those studies indicate that PPARγ agonists at appropriate "therapeutic" doses protect brain tissues from I/R damage in a PPARγ-dependent manner. 15d-PGJ 2 and rosiglitazone administration is accompanied by a significant reduction of apoptotic markers in the I/R damaged brain [35, 38] . The in vitro cellular studies have revealed that rosiglitazone protects neurons from apoptosis induced by hypoxia/reoxygenation [35] . Taken together, these data suggest that rosiglitazone protects neurons from apoptosis in the brain tissues damaged by I/R. To identify the effector protein that mediates the antiapoptotic action of PPAR-γ agonists, we analyzed brain tissues by proteomics [35] . Ischemic brain tissues from rats treated with or without rosiglitazone are collected and processed, and the lysate proteins from the tissues are analyzed by two-dimensional electrophoresis. A number of protein spots are enhanced in rosiglitazone-treated brain tissues. The spot that exhibits the highest increase (>5 fold) is removed and analyzed by tandem mass spectrometry. This protein spot matches 14-3-3ε. Western blot analysis of brain tissues confirms elevation of 14-3-3ε proteins in rosiglitazonetreated brain tissues. 14-3-3ε elevation in rosiglitazonetreated tissues is abrogated by concurrent administration of PPARγ siRNA. Rosiglitazone-induced 14-3-3ε upregulation plays an important role in protecting against I/R-induced cerebral infarction. Silencing of brain 14-3-3ε with 14-3-3ε siRNA administration abrogates the anti-infarct effect of rosiglitazone while administration of 14-3-3ε attenuates I/Rinduced infarction. Results from the in vivo experiments suggest that rosiglitazone at the concentrations used in our experiments protects brain tissues against I/R-induced damage via PPARγ/14-3-3ε. It is unclear whether the negative effect of rosiglitazone at higher concentrations is related to 14-3-3ε suppression.
Rosiglitazone Enhances PPARγ Binding to and Activation of 14-3-3ε Promoter
Ligand-activated PPARγ exerts its biological actions by suppressing the expression of proinflammatory genes through NF-κB-dependent transcriptional mechanism [39, 40] . It stimulates the expression of a small number of genes and little is known about its transcriptional mechanism. Our studies show that rosiglitazone induces PPARγ binding to the PPREs of 14-3-3ε promoter/enhancer and activates 14-3-3ε transcription. In a neuronal cell model, rosiglitazone increases 14-3-3ε promoter activity and its effect is abrogated when the PPRE region is deleted from the 14-3-3ε promoter construct. Chromatin immunoprecipitation analysis reveals that rosiglitazone induces PPARγ binding to the region harboring PPAR response elements. Corresponding to 14-3-3ε promoter activation, rosiglitazone increases 14-3-3ε protein expression which is abrogated by GW9662, a PPARγ antagonist, and by PPARγ siRNA. Rosiglitazone-induced 14-3-3ε plays a crucial role in protecting neuronal cells from apoptosis induced by hypoxia and reoxygenation [35] . Knockdown of 14-3-3ε with 14-3-3ε siRNA abrogated the protective effect of rosiglitazone, while 14-3-3ε overexpression attenuates hypoxia-induced apoptosis. The protective effect of PPARγ overexpression is 4 PPAR Research also abrogated by 14-3-3ε siRNA. Taken together, the findings indicate that the PPARγ-mediated 14-3-3ε upregulation represents an important mechanism by which PPARγ ligands protect cells and tissues from I/R damage.
Several reports have shown that rosiglitazone and other glitazones protect neuronal survival accompanied by increased Bcl-2 expression [41] . We have shown that rosiglitazone rescues Bcl-2 but not Bcl-XL in neurons from hypoxia/reoxygenation-induced repression [42] . As 14-3-3ε upregulation increases Bad sequestration, and, therefore, reduces Bad translocation to mitochondria to interfere with the protective action of Bcl-2, an enhanced Bcl-2 expression should further strengthen the protection of mitochondrial membrane potential and reduction of apoptosis.
PPARα Ligands Protect against I/R Tissue Damage and Cell Death
PPARα is activated by fatty acids, eicosanoids, and synthetic ligand such as fibrates, which are clinically used in treating dyslipidemia [43, 44] . In addition to their effects on glucose homeostasis and lipid metabolism [43] , PPARα ligands inhibit NF-κB and AP-1 transactivation resulting in suppressing the expression of proinflammatory genes such as cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and adhesive molecules ICAM-1 and VCAM-1 [45] [46] [47] [48] . Ligand-activated PPARα induces the expression of antioxidant enzymes including superoxide dismutase and catalase [49, 50] . Thus, ligand-activated PPARα possesses anti-inflammatory and antioxidation properties.
Based on their potent anti-inflammatory and antioxidation actions, the synthetic PPARα ligands, fibrates, have been used to control I/R-induced tissue injury. Chronic fenofibrate administration was shown to reduce infarct volume in a mouse middle cerebral artery occlusion model [51] . PGI 2 overproduction via Ad-COPI gene transfer was shown to reduce renal I/R injury through PPARα nuclear translocation [52] . WY14643 was reported to ameliorate cisplatin-induced renal damage [53] . Although the protective effects of PPARα ligands on diverse I/R-induced tissue injuries are attributed to control of inflammatory and oxidative tissue damage, a number of reports indicate that ligand-activated PPARα protects against apoptosis. For example, it was reported that PGI 2 or docosahexaenoic acid protects renal cells from toxininduced apoptosis [54, 55] ; fenofibrate inhibits aldosteroneinduced myocardiocyte apoptosis [56] and WY14643 prevents neonatal cardiomyocyte apoptosis induced by glucose and fatty acids [57] . The anti-apoptotic actions of ligandactivated PPARα are likely to make significant contributions to protect tissues from I/R damage.
The mechanism by which PPARα protects against apoptosis remains to be elucidated. We postulate that ligandactivated PPARα confers anti-apoptotic protection also through binding to 14-3-3ε promoter and upregulating 14-3-3ε expression. The rationale for the proposed hypothesis is based on (1) high-sequence homology and structural similarity of PPARα DNA binding domain with its counterparts in PPARγ and PPARδ, (2) identical cis-regulatory element motif that is recognized by PPARα, PPARγ, and PPARδ, and (3) requirement of identical heterodimer partner, RXR for DNA binding. Work is in progress to test this hypothesis.
PPARs Defend against Mitochondrial Death Pathway by a Coordinated Common Mechanism
Based on findings reported by several laboratories including ours, we propose a common mechanism by which all three PPAR isoforms protect cells from oxidative mitochondrial damage and thereby defend against apoptosis via the intrinsic death pathway. As illustrated in Figure 1 , PPARα, γ, or δ activated by their respective ligands forms heterodimers with RXR which binds to the PPRE sites on the 14-3-3ε promoter and upregulates the transcription of 14-3-3ε. Enhanced 14-3-3ε augments binding and sequestration of Bad, and thereby reduces interference of Bcl-2 and Bcl-xl protective actions by Bad [58] [59] [60] [61] . Mitochondrial membrane potential is maintained, and release of pro-apoptotic cofactors such as cytochrome C and Diablo is blocked when cells are challenged by oxidative stress and cytotoxic insults [58] . This results in reduction of caspase activation and caspaseinduced apoptotic changes.
Reported data indicate that ligand-activated PPARγ activates Akt which phosphorylates Bad and enhances Bad binding by 14-3-3 [15, 33, 62] . Furthermore, ligand-activated PPARγ stimulates Bcl-2 generation which enforces the mitochondrial protection [21, 42] . It is unclear whether ligand-activated PPARα and PPARδ have similar actions as PPARγ on Akt activation and/or Bcl-2 upregulation.
Therapeutic Implications
Ischemia-reperfusion tissue damage is one of the most important pathophysiological processes that cause major human diseases such as myocardial infarction (MI), stroke, and kidney diseases. Since PPARα and PPARδ ligands are unequivocally effective in preventing and interrupting I/R-induced infarction in experimental animals, they have potentials for therapeutic use in early treatment of MI, renal diseases, and stroke. Some of the synthetic agonists of PPARα (the fibrates) and PPARδ (PGI 2 analogs) are already in use clinically for treating lipid and vascular disorders, respectively, and new compounds are undergoing clinical trials. Those drugs should be good candidates for therapy of MI, stroke, and other tissue infarctions. PPARα and PPARδ may be used individually or in combination. Some compounds such as carbaprostacyclin bind and activate PPARδ and PPARα and are well suited for therapeutic purposes.
The effects of PPARγ agonists on controlling I/R damage are complex and dose-dependent because of their pleiotropic actions, some of which are independent of PPARγ-transcriptional activities. Hence, despite beneficial effects reported by a majority of studies, PPARγ agonists may be associated with adverse effects. Further studies are needed to unravel the mechanisms by which PPARγ agonists exert a biphasic effects on cytoprotection.
PPARs/14-3-3ε axis may serve as targets for new drug discovery. Compounds that selectively activate this transcriptional pathway will be more specific and more potent in cell and tissue protection and possess less adverse effects.
